Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of E7080 in Subjects With Solid Tumors
jRCT2080221345Phase 1
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenvatinib in Nonhematologic neoplasms, sponsored by Eisai Co., Ltd. Primary endpoints: Dose-limiting toxicity (DLT) during initial treatment period and Safety and tolerability.
02
Drugs
lenvatinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080221345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221345.